Press release
United States Neurotherapeutics Market Projected to Expand at 4.9% CAGR, Reaching USD 11.10 Billion by 2033 | DataM Intelligence
Neurotherapeutics Market
United States: Recent Industry Developments
✅ In September 2025, The FDA approved a novel gene therapy for Parkinson's disease, demonstrating significant motor symptom improvement in clinical trials.
✅ In August 2025, Biogen launched a new digital therapeutic platform for cognitive rehabilitation in Alzheimer's patients.
✅ In July 2025, The NIH announced a $500 million initiative for advancing neurostimulation technologies for treatment-resistant depression.
Japan: Recent Industry Developments
✅ In September 2025, Takeda Pharmaceutical received approval for a new migraine prevention therapy with novel mechanism of action.
✅ In August 2025, Japan's PMDA fast-tracked review of a breakthrough therapy for ALS based on promising clinical data.
✅ In July 2025, Otsuka Pharmaceutical partnered with a tech company to develop AI-based diagnostics for early detection of neurological disorders.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/neurotherapeutics-market?jd
Market Trends & Drivers
The Neurotherapeutics Market is driven by increasing prevalence of neurological disorders, aging populations, and advancements in precision medicine. Growing understanding of brain circuitry, expansion of biomarker research, and development of targeted therapies are accelerating market growth. Rising healthcare expenditure on neurological care, coupled with technological innovations in neurostimulation and digital therapeutics, further fuels market expansion globally.
Competitive Landscape
The market features strong competition among pharmaceutical companies and biotechnology firms specializing in neurological treatments.
Biogen Inc. leads with multiple sclerosis and Alzheimer's therapies, advancing research in neurodegenerative diseases.
Novartis AG maintains a strong portfolio with innovative treatments for migraine, multiple sclerosis, and spinal muscular atrophy.
Roche Holding AG focuses on neurology with targeted therapies for multiple sclerosis and neuromuscular disorders.
Pfizer Inc. advances its neuroscience pipeline with novel mechanisms for Alzheimer's and Parkinson's diseases.
Johnson & Johnson develops comprehensive solutions for neurological conditions including epilepsy and stroke.
Eli Lilly and Company specializes in Alzheimer's research and migraine prevention therapies.
Merck & Co., Inc. invests in novel approaches for neurodegenerative diseases and neuroinflammatory conditions.
UCB S.A. focuses on epilepsy and Parkinson's disease with specialized therapeutic solutions.
Teva Pharmaceutical Industries maintains leadership in multiple sclerosis and movement disorder treatments.
AbbVie Inc. (including Allergan) develops innovative therapies for migraine and neurological pain conditions.
Segmentation
By Treatment Type (Neurological Drugs, Neurological Devices)
By Application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Epilepsy, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury, Others)
By End-User (Hospitals, Specialty Clinics, Academic & Research Institutes, Others)
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/neurotherapeutics-market?jd
Regional Analysis:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?jd
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us:
At DataM Intelligence, we provide more than just data-we deliver end-to-end business solutions. From deep-dive research to strategic consulting, we partner with you to turn complex market trends into a clear competitive advantage.
Leveraging our extensive database of 6,300+ reports across 40+ domains, we offer the insights and astute recommendations you need to make confident decisions. We are proud to support 200+ companies worldwide in navigating their key business challenges and accelerating their growth trajectory.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Neurotherapeutics Market Projected to Expand at 4.9% CAGR, Reaching USD 11.10 Billion by 2033 | DataM Intelligence here
News-ID: 4218148 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Brain Health Supplements Market valuation $11.71 billion by 2033 - …
"The global brain health supplements market size reached US$ 7.66 Billion with rise of US$ 7.97 Billion in 2024 is expected to reach US$ 11.71 Billion by 2033, growing at a CAGR of 4.4% during the forecast period 2025-2033." As per DataM intelligence research report
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/brain-health-supplements-market?sp
United States: Recent Industry Developments
✅ In October 2025, JOURTHON introduced a Brain Health Softgel supporting…
United States Smart Medical Devices Market Projected to Expand at 12.8% CAGR, Re …
The global Smart Medical Devices Market reached USD 61.66 Billion in 2024 and is projected to reach USD 180.38 Billion by 2033, growing at a CAGR of 12.8% during the forecast period 2025-2033, according to DataM Intelligence.
United States: Recent Industry Developments
✅ In September 2025, The FDA granted clearance to a new AI-powered continuous glucose monitoring system with predictive hypoglycemia alerts.
✅…
United States Drugs of Abuse Testing Products Market 2025 | Growth Drivers, Key …
Market Size and Growth
The global drugs-of-abuse testing products market size is estimated to reach at a high CAGR during the forecast period 2023-2030
Key Development:
United States: Recent Industry Developments
✅ In October 2025, the U.S. FDA launched a pilot program to expedite the review of generic drugs tested and manufactured domestically. This initiative aims to strengthen the U.S. drug supply chain and reduce reliance on foreign production.
Japan: Recent Industry Developments
✅ In June…
United States Waldenstrom Macroglobulinemia Market Size, Share, Trends - Exclusi …
"Waldenstrom Macroglobulinemia market is estimated to reach at a high CAGR during the forecast period 2024-2031." As per DataM intelligence research report
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/waldenstrom-macroglobulinemia-market?sp
United States: Recent Industry Developments
✅ In July 2025, Cellectar Biosciences announced the US FDA granted Breakthrough Therapy Designation for iopofosine I 131 in Waldenstrom macroglobulinemia. This designation accelerates the development and review of this promising targeted radiopharmaceutical therapy.…
More Releases for Neurotherapeutics
United States Neurotherapeutics Industry Analysis 2025 | Market Size, Growth Dri …
Neurotherapeutics market size reached US$7.28Billion in 2024 from US$6.97Billionin 2023 and is expected to reach US$ 11.10Billion by 2033, growing at a CAGR of 4.9%during the forecast period 2025-2033.
DataM Intelligence unveils its latest report on the "Neurotherapeutics Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can…
Neurology Market Set to Witness Strong Growth Backed by Advances in Neurotherape …
Neurology Market Overview
The Neurology Market is anticipated to grow from USD 112.5 Billion in 2025 to USD 180.2 Billion by 2032, registering a CAGR of 6.9%.
Coherent Market Insights is pleased to release its latest Neurology Market research report, offering an in-depth analysis of the U.S. Neurology Market Landscape from 2025 to 2032. This report delivers reliable projections across national and regional levels, encompassing supply chain shifts, payer-provider dynamics, and competitive…
Neurotherapeutics Market Report: Market Dynamics and Key Drivers
When any business seek to lead the market or make a mark in the market as a fresh emergent, market research report is always central. A comprehensive Neurotherapeutics Market report encompasses a market data that provides a detailed analysis of the ABC industry and its impact based on applications and different geographical regions. The report gives current as well as upcoming technical and financial details of the industry to 2027.…
Chorea Treatment Market Size,Share,Trend 2026|Medtronic, Boston Scientific, Alev …
Los Angeles, United State, , - The report on the global Chorea Treatment market is comprehensively prepared with main focus on the competitive landscape, geographical growth, segmentation, and market dynamics, including drivers, restraints, and opportunities. It sheds light on key production, revenue, and consumption trends so that players could improve their sales and growth in the Global Chorea Treatment Market. It offers a detailed analysis of the competition and leading…
In-Depth Analysis on Global Neurotherapeutics Industry Report 2016–2021
Neurologic disorders are defined as a change in the function of a nervous system. These are mainly caused due to structural change in activity of spinal cord, brain, and other nerves. These disorders are classified into three type’s namely Central nervous system disorders, Peripheral nervous system disorders, Autonomous nervous system disorders. These disorders involve progressive deterioration in mental and physical capabilities which disrupts the patient and patient’s family.
View report: http://www.marketdataforecast.com/market-reports/global-neurotherapeutics-market-1270/
Genetic…
Aleva Neurotherapeutics Raises CHF 4.0 Million in Series B Financing Round
- Lead investor Banexi Ventures Partners joins strong investment consortium -
Lausanne, Switzerland, April 10, 2012 – Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, today announced the closing of a Series B financing round totaling CHF 4.0 million.
Banexi Ventures Partners acted as a lead investor in the financing, with selected private investors also participating in…
